Results 21 to 30 of about 68,171 (350)

Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder

Drug and Alcohol Dependence Reports, 2022
Introduction: Psychosocial support is recommended in conjunction with medication for opioid use disorder (MOUD), although optimal “dose,” modality, and timing of participation is not established.
Kathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, Martina Pavlicova, Jacquie King, Marc Fishman, Matisyahu Shulman, Aimee Campbell, Miranda Greiner, Jennifer Scodes, Sarah Meyers-Ohki, Patricia Novo, Edward Nunes, John Rotrosen   +13 more
doaj   +1 more source

Advancing emergency department–initiated buprenorphine

Journal of the American College of Emergency Physicians Open, 2021
Opioids are the main driver of drug overdose deaths in the United States, and there has been a marked increase in opioid‐related overdoses during the COVID‐19 public health emergency.
Kristen Huntley, Emily Einstein, Terri Postma, Anita Thomas, Shari Ling, Wilson Compton   +5 more
doaj   +1 more source

Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems

Addiction Science & Clinical Practice, 2021
Purpose Little is known about prevalence and treatment of OUD among youth engaged in primary care (PC). Medications are the recommended treatment of opioid use disorder (OUD) for adolescents and young adults (youth).
Sarah M. Bagley, Laura Chavez, Jordan M. Braciszewski, Mary Akolsile, Denise M. Boudreau, Gwen Lapham, Cynthia I. Campbell, Gavin Bart, Bobbi Jo H. Yarborough, Jeffrey H. Samet, Andrew J. Saxon, Rebecca C. Rossom, Ingrid A. Binswanger, Mark T. Murphy, Joseph E. Glass, Katharine A. Bradley, PROUD Collaborative   +16 more
doaj   +1 more source

Medications for management of opioid use disorder

American Journal of Health-System Pharmacy, 2019
Abstract Purpose The use of buprenorphine, methadone, and long-acting naltrexone for treatment of opioid use disorder (OUD) is discussed, including a review of current literature detailing treatment approaches and action steps to optimize treatment in acute care and office-based settings.
Jennifer L, Koehl, David E, Zimmerman, Patrick J, Bridgeman   +2 more
openaire   +2 more sources

Single high-dose buprenorphine for opioid craving during withdrawal. [PDF]

, 2018
BackgroundOpioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a ...
Ahmadi, Jamshid, Ghahremani, Dara, Jahromi, Mina Sefidfard, London, Edythe D   +3 more
core   +2 more sources

Evaluating the optimal duration of medication treatment for opioid use disorder [PDF]

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, M Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
openalex   +2 more sources

Medication for opioid use disorder at hospital discharge is not associated with intravenous antibiotic completion in post-acute care facilities

Therapeutic Advances in Infectious Disease, 2022
Background: People with opioid use disorder and severe infections may complete their prolonged courses of outpatient parenteral antimicrobial therapy at a post-acute care facility due to adherence and safety concerns.
Edward C. Traver, Patrick R. Ching, Shivakumar Narayanan   +2 more
doaj   +1 more source

Stigma as a fundamental hindrance to the United States opioid overdose crisis response. [PDF]

, 2019
Alexander Tsai and co-authors discuss the role of stigma in responses to the US opioid ...
Barnett, Michael L, Beletsky, Leo, Keyes, Katherine M, Kiang, Mathew V, McGinty, Emma E, Smith, Laramie R, Strathdee, Steffanie A, Tsai, Alexander C, Venkataramani, Atheendar S, Wakeman, Sarah E   +9 more
core   +2 more sources

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

Hepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman, Neehar Parikh, Dan J. Clauw, David A. Williams, Elliot B. Tapper   +4 more
wiley   +1 more source

The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder

Addiction Science & Clinical Practice, 2022
Background People with opioid use disorder experience high burden of disease from medical comorbidities and are increasingly hospitalized with medical complications.
Allison J. Ober, Cristina Murray-Krezan, Kimberly Page, Peter D. Friedmann, Karen Chan Osilla, Stephen Ryzewicz, Sergio Huerta, Mia W. Mazer, Isabel Leamon, Gabrielle Messineo, Katherine E. Watkins, Teryl Nuckols, Itai Danovitch   +12 more
doaj   +1 more source